Recent Updates
Recently added Catalysts
IMCC Positive Sentiment Score: 70/100

IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET

Key Takeaway: IM Cannabis Corp. will report its financial results for the first quarter of 2025 on May 15, 2025. The company, which operates in Israel and Germany, will conduct a web conference at 9:00 AM ET to discuss its performance and answer investor questions. This event emphasizes IMC's commitment to transparency and investor relations as they navigate the medical cannabis market.

Market Sentiment Analysis

POSITIVE FACTORS

  • Company is preparing to report first quarter 2025 financial results, indicating activity and progress.
  • An interactive Q&A session is planned for investors, promoting transparency and engagement.
  • The company's focus on sustainable and profitable growth showcases long-term strategic vision.

Full Press Release Details

TORONTO and GLIL YAM, Israel, May 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2025 ended March 31, 2025, on Thursday, May 15, 2025, before the market opens.
The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.
If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com within 24 hours after the call.
Link for the zoom call:
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Anna Taranko, Director Investor & Public Relations
SOURCE IM Cannabis Corp.

21 %

more press release views with

Frequently Asked Questions

When will IM Cannabis report Q1 2025 results?

IM Cannabis will report Q1 2025 results on May 15, 2025, before market opens.

How can investors join the IM Cannabis conference call?

Investors can register for the conference call via a link provided in the announcement.

Where can I find the recording of the conference call?

A recording will be available on the IM Cannabis website within 24 hours post-call.

What markets does IM Cannabis primarily operate in?

IM Cannabis operates mainly in the medical cannabis markets of Israel and Germany.

Who distributes cannabis in Germany for IM Cannabis?

In Germany, Adjupharm GmbH handles the distribution of cannabis to pharmacies.

Last updated: May 6, 2025